{"protocolSection": {"identificationModule": {"nctId": "NCT00306163", "orgStudyIdInfo": {"id": "BY9010/NL-101"}, "organization": {"fullName": "AstraZeneca", "class": "INDUSTRY"}, "briefTitle": "Responsiveness of Lower Airways in Adult Patients (18-60 Years) With Stable Asthma After Treatment With Ciclesonide and Fluticasone Propionate (BY9010/NL-101)", "officialTitle": "Nebulizer Trial: Evaluation of the Influence of Particle Size of Aerosolized AMP on Bronchial Responsiveness in Patients With Asthma and the Effects of Treatment With Ciclesonide Versus Fluticasone."}, "statusModule": {"statusVerifiedDate": "2016-09", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2006-05"}, "primaryCompletionDateStruct": {"date": "2008-08", "type": "ACTUAL"}, "completionDateStruct": {"date": "2008-09", "type": "ACTUAL"}, "studyFirstSubmitDate": "2006-03-22", "studyFirstSubmitQcDate": "2006-03-22", "studyFirstPostDateStruct": {"date": "2006-03-23", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2010-04-06", "resultsFirstSubmitQcDate": "2010-04-06", "resultsFirstPostDateStruct": {"date": "2010-04-26", "type": "ESTIMATED"}, "dispFirstSubmitDate": "2009-11-19", "dispFirstSubmitQcDate": "2010-04-06", "dispFirstPostDateStruct": {"date": "2010-04-26", "type": "ESTIMATED"}, "lastUpdateSubmitDate": "2016-12-02", "lastUpdatePostDateStruct": {"date": "2017-02-01", "type": "ESTIMATED"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "AstraZeneca", "class": "INDUSTRY"}}, "oversightModule": {"oversightHasDmc": false}, "descriptionModule": {"briefSummary": "The aim of this study is to compare the responsiveness of lower airways in adult patients with stable asthma after treatment with ciclesonide and fluticasone propionate. Treatment medication will be administered as follows: ciclesonide will be inhaled once daily at one dose level, fluticasone propionate will be inhaled twice daily at one dose level. The study duration consists of a baseline period (5 weeks) and a treatment period (5 weeks). The study will provide further data on safety and tolerability of ciclesonide."}, "conditionsModule": {"conditions": ["Asthma"], "keywords": ["Asthma", "AMP", "Ciclesonide", "Fluticasone propionate"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE3"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "PARALLEL", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "TRIPLE", "whoMasked": ["PARTICIPANT", "CARE_PROVIDER", "INVESTIGATOR"]}}, "enrollmentInfo": {"count": 37, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "1", "type": "ACTIVE_COMPARATOR", "description": "Ciclesonide 160 \u00b5g", "interventionNames": ["Drug: Ciclesonide"]}, {"label": "2", "type": "ACTIVE_COMPARATOR", "description": "Fluticasone 100 \u00b5g", "interventionNames": ["Drug: Fluticasone"]}], "interventions": [{"type": "DRUG", "name": "Ciclesonide", "description": "inhaled Ciclesonide 160 \u00b5g, once daily in the morning", "armGroupLabels": ["1"]}, {"type": "DRUG", "name": "Fluticasone", "description": "inhaled Fluticasone 100 \u00b5g, twice daily", "armGroupLabels": ["2"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "PC20 AMP (Post-treatment Compared to Baseline)", "description": "Mean change of Provocative concentration of Adenosine-5'-monophosphate (PC20 AMP) leading to a 20 percent decrease in Forced expiratory volume in one second (FEV1) between post-treatment and baseline using two different particle sizes. - Small particles = Mass mean aerodynamic diameter (MMAD) of approximately 1.04-1.08 micron - Large particles = MMAD of approximately 9.9-10.6 micron", "timeFrame": "Baseline and 5 weeks"}], "secondaryOutcomes": [{"measure": "\u0394 (FVC/SVC) at PC20 (AMP)", "description": "Change between baseline and post-treatment of the ratio of Forced Vital Capacity (FVC) and Slow Vital Capacity at PC20. Measured with either small or large partical size AMP.", "timeFrame": "Baseline and 5 weeks"}, {"measure": "Safety and Tolerability", "timeFrame": "5 weeks"}]}, "eligibilityModule": {"eligibilityCriteria": "Main Inclusion Criteria:\n\n* History of bronchial asthma\n* FEV1 \\> 1.20 L\n* Positive Skin Prick Test\n* Not more than 500 mcg/day fluticasone propionate or equivalent for at least 28 days prior to baseline visit\n\nMain Exclusion Criteria:\n\n* Clinically relevant abnormal laboratory values\n* Concomitant severe diseases, diseases expected to interfere with the outcome of the study and diseases which are contra-indications for the use of inhaled steroids\n* Chronic obstructive pulmonary disease (COPD) and /or other relevant lung diseases\n* One asthma exacerbation within 2 months or more than 3 exacerbations within the last year prior to baseline visit\n* Current smokers or ex-smokers with more than 10 pack years, or having smoked within 1 year prior to baseline visit\n* Positive response to saline challenge at baseline visits\n* Positive bronchial hyperresponsiveness", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "18 Years", "maximumAge": "60 Years", "stdAges": ["ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "AstraZeneca AstraZeneca", "affiliation": "AstraZeneca", "role": "STUDY_DIRECTOR"}], "locations": [{"facility": "Altana Pharma/Nycomed", "city": "RB Groningen", "zip": "9700", "country": "Netherlands"}]}, "referencesModule": {"references": [{"pmid": "20595155", "type": "DERIVED", "citation": "Cohen J, Postma DS, Douma WR, Vonk JM, De Boer AH, ten Hacken NH. Particle size matters: diagnostics and treatment of small airways involvement in asthma. Eur Respir J. 2011 Mar;37(3):532-40. doi: 10.1183/09031936.00204109. Epub 2010 Jul 1."}]}}, "resultsSection": {"participantFlowModule": {"preAssignmentDetails": "A total of 101 subjects gave Informed Consent. 64 subjects did not enter or discontinued the study due to various reasons.", "groups": [{"id": "FG000", "title": "Ciclesonide", "description": "160 \u00b5g, once daily"}, {"id": "FG001", "title": "Fluticasone", "description": "100 \u00b5g, twice daily"}], "periods": [{"title": "Overall Study", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "19"}, {"groupId": "FG001", "numSubjects": "18"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "19"}, {"groupId": "FG001", "numSubjects": "18"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}]}]}]}, "baselineCharacteristicsModule": {"groups": [{"id": "BG000", "title": "Ciclesonide", "description": "160 \u00b5g, once daily"}, {"id": "BG001", "title": "Fluticasone", "description": "100 \u00b5g, twice daily"}, {"id": "BG002", "title": "Total", "description": "Total of all reporting groups"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "19"}, {"groupId": "BG001", "value": "18"}, {"groupId": "BG002", "value": "37"}]}], "measures": [{"title": "Age, Continuous", "description": "Statistics for the total value were not available. The cited numbers are the results of manual calculations.", "paramType": "MEDIAN", "dispersionType": "INTER_QUARTILE_RANGE", "unitOfMeasure": "years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "39.61", "spread": "10.50", "lowerLimit": "32.54", "upperLimit": "46.64"}, {"groupId": "BG001", "value": "46.02", "spread": "9.80", "lowerLimit": "37.85", "upperLimit": "55.52"}, {"groupId": "BG002", "value": "42.25", "spread": "10.16", "lowerLimit": "37.58", "upperLimit": "51.75"}]}]}]}, {"title": "Gender", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "13"}, {"groupId": "BG001", "value": "8"}, {"groupId": "BG002", "value": "21"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "6"}, {"groupId": "BG001", "value": "10"}, {"groupId": "BG002", "value": "16"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "PC20 AMP (Post-treatment Compared to Baseline)", "description": "Mean change of Provocative concentration of Adenosine-5'-monophosphate (PC20 AMP) leading to a 20 percent decrease in Forced expiratory volume in one second (FEV1) between post-treatment and baseline using two different particle sizes. - Small particles = Mass mean aerodynamic diameter (MMAD) of approximately 1.04-1.08 micron - Large particles = MMAD of approximately 9.9-10.6 micron", "populationDescription": "The analyses on treatment effects were performed on all subjects who reached a PC20\\<640mg/mL.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "Logarithm (mg/mL)", "timeFrame": "Baseline and 5 weeks", "groups": [{"id": "OG000", "title": "Ciclesonide", "description": "160 \u00b5g, once daily"}, {"id": "OG001", "title": "Fluticasone", "description": "100 \u00b5g, twice daily"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "11"}, {"groupId": "OG001", "value": "12"}]}], "classes": [{"title": "Baseline PC20 small-particle AMP", "categories": [{"measurements": [{"groupId": "OG000", "value": "4.9", "spread": "3.7"}, {"groupId": "OG001", "value": "5.2", "spread": "2.1"}]}]}, {"title": "Baseline PC20 large-particle AMP", "categories": [{"measurements": [{"groupId": "OG000", "value": "3.7", "spread": "2.6"}, {"groupId": "OG001", "value": "3.0", "spread": "2.4"}]}]}, {"title": "Post-Treatment PC20 small-particle AMP", "categories": [{"measurements": [{"groupId": "OG000", "value": "6.6", "spread": "2.0"}, {"groupId": "OG001", "value": "6.0", "spread": "2.7"}]}]}, {"title": "Post-Treatment PC20 large-particle AMP", "categories": [{"measurements": [{"groupId": "OG000", "value": "4.5", "spread": "2.3"}, {"groupId": "OG001", "value": "4.3", "spread": "2.4"}]}]}]}, {"type": "SECONDARY", "title": "\u0394 (FVC/SVC) at PC20 (AMP)", "description": "Change between baseline and post-treatment of the ratio of Forced Vital Capacity (FVC) and Slow Vital Capacity at PC20. Measured with either small or large partical size AMP.", "reportingStatus": "NOT_POSTED", "timeFrame": "Baseline and 5 weeks", "denomUnitsSelected": "Participants"}, {"type": "SECONDARY", "title": "Safety and Tolerability", "reportingStatus": "NOT_POSTED", "timeFrame": "5 weeks", "denomUnitsSelected": "Participants"}]}, "adverseEventsModule": {"frequencyThreshold": "5", "eventGroups": [{"id": "EG000", "title": "Ciclesonide", "description": "160 \u00b5g, once daily", "seriousNumAffected": 0, "seriousNumAtRisk": 19, "otherNumAffected": 2, "otherNumAtRisk": 19}, {"id": "EG001", "title": "Fluticasone", "description": "100 \u00b5g, twice daily", "seriousNumAffected": 0, "seriousNumAtRisk": 18, "otherNumAffected": 2, "otherNumAtRisk": 18}], "otherEvents": [{"term": "Urticaria", "organSystem": "Skin and subcutaneous tissue disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 19}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 18}]}, {"term": "Common cold", "organSystem": "Infections and infestations", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 19}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 18}]}, {"term": "Pain armpit", "organSystem": "General disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 19}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 18}]}, {"term": "Inflammation of the throat", "organSystem": "Respiratory, thoracic and mediastinal disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 19}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 18}]}]}, "moreInfoModule": {"certainAgreement": {"piSponsorEmployee": false, "restrictionType": "GT60", "restrictiveAgreement": true}, "pointOfContact": {"title": "AstraZeneca Clinical Study Information Center", "organization": "AstraZeneca", "email": "information.center@astrazeneca.com", "phone": "1-877-240-9479"}}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-06-24"}, "conditionBrowseModule": {"meshes": [{"id": "D000001249", "term": "Asthma"}], "ancestors": [{"id": "D000001982", "term": "Bronchial Diseases"}, {"id": "D000012140", "term": "Respiratory Tract Diseases"}, {"id": "D000008173", "term": "Lung Diseases, Obstructive"}, {"id": "D000008171", "term": "Lung Diseases"}, {"id": "D000012130", "term": "Respiratory Hypersensitivity"}, {"id": "D000006969", "term": "Hypersensitivity, Immediate"}, {"id": "D000006967", "term": "Hypersensitivity"}, {"id": "D000007154", "term": "Immune System Diseases"}], "browseLeaves": [{"id": "M4556", "name": "Asthma", "asFound": "Asthma", "relevance": "HIGH"}, {"id": "M5258", "name": "Bronchial Diseases", "relevance": "LOW"}, {"id": "M14977", "name": "Respiratory Tract Diseases", "relevance": "LOW"}, {"id": "M11168", "name": "Lung Diseases", "relevance": "LOW"}, {"id": "M11170", "name": "Lung Diseases, Obstructive", "relevance": "LOW"}, {"id": "M10018", "name": "Hypersensitivity", "relevance": "LOW"}, {"id": "M14967", "name": "Respiratory Hypersensitivity", "relevance": "LOW"}, {"id": "M10020", "name": "Hypersensitivity, Immediate", "relevance": "LOW"}, {"id": "M10200", "name": "Immune System Diseases", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC08", "name": "Respiratory Tract (Lung and Bronchial) Diseases"}, {"abbrev": "BC20", "name": "Immune System Diseases"}, {"abbrev": "All", "name": "All Conditions"}]}, "interventionBrowseModule": {"meshes": [{"id": "D000068298", "term": "Fluticasone"}, {"id": "C000120481", "term": "Ciclesonide"}], "ancestors": [{"id": "D000000893", "term": "Anti-Inflammatory Agents"}, {"id": "D000001993", "term": "Bronchodilator Agents"}, {"id": "D000001337", "term": "Autonomic Agents"}, {"id": "D000018373", "term": "Peripheral Nervous System Agents"}, {"id": "D000045505", "term": "Physiological Effects of Drugs"}, {"id": "D000018927", "term": "Anti-Asthmatic Agents"}, {"id": "D000019141", "term": "Respiratory System Agents"}, {"id": "D000003879", "term": "Dermatologic Agents"}, {"id": "D000018926", "term": "Anti-Allergic Agents"}, {"id": "D000005938", "term": "Glucocorticoids"}, {"id": "D000006728", "term": "Hormones"}, {"id": "D000006730", "term": "Hormones, Hormone Substitutes, and Hormone Antagonists"}], "browseLeaves": [{"id": "M250", "name": "Fluticasone", "asFound": "Pembrolizumab", "relevance": "HIGH"}, {"id": "M353494", "name": "Xhance", "relevance": "LOW"}, {"id": "M221371", "name": "Ciclesonide", "asFound": "Rigid", "relevance": "HIGH"}, {"id": "M4217", "name": "Anti-Inflammatory Agents", "relevance": "LOW"}, {"id": "M5269", "name": "Bronchodilator Agents", "relevance": "LOW"}, {"id": "M20963", "name": "Anti-Asthmatic Agents", "relevance": "LOW"}, {"id": "M21137", "name": "Respiratory System Agents", "relevance": "LOW"}, {"id": "M7074", "name": "Dermatologic Agents", "relevance": "LOW"}, {"id": "M20962", "name": "Anti-Allergic Agents", "relevance": "LOW"}, {"id": "M9047", "name": "Glucocorticoids", "relevance": "LOW"}, {"id": "M9789", "name": "Hormones", "relevance": "LOW"}, {"id": "M9788", "name": "Hormone Antagonists", "relevance": "LOW"}], "browseBranches": [{"abbrev": "AAll", "name": "Anti-Allergic Agents"}, {"abbrev": "Infl", "name": "Anti-Inflammatory Agents"}, {"abbrev": "Derm", "name": "Dermatologic Agents"}, {"abbrev": "Resp", "name": "Respiratory System Agents"}, {"abbrev": "All", "name": "All Drugs and Chemicals"}]}}, "hasResults": true}